New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

NEXT STORY
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners
PREV STORY
VitalHub Announces Large-Scale Expansion Licensing Deal and Upgrade to Virtual Care Module with King’s College Hospital NHS Foundation Trust
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

author_avatar
NASDAQ Market News

Myriad Genetics Completes Acquisition of Assurex Health

SALT LAKE CITY, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) a ...

author_avatar
NASDAQ Market News

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News